SAN ANTONIO, Texas — Powerhouse Therapeutics Inc announced today that it will present new data on its lead candidate, PH102, at the 2025 San Antonio Liver Cancer Symposium (SALCS). The presentation, titled “Remodeling the Immune ‘Cold’ Hepatocellular Carcinoma Tumor Microenvironment with PH102: An Armed CAR T Cell Therapy,” will showcase the company's Immune Triad Therapy with Armed CAR T-Cell Supercharger (IT-ACTS) platform and its potential to overcome treatment resistance in hepatocellular carcinoma (HCC).
Liver cancer represents a significant public health challenge, particularly in Texas, where rates of hepatocellular carcinoma are nearly double those seen across the United States. This disparity highlights the urgent need for new therapeutic approaches that can improve outcomes for patients who face a disease with limited treatment options and poor prognosis.
The oral presentation will take place on Thursday, October 9, 2025, from 1:45 to 2:00 PM CST in the General Session Room at The Westin San Antonio North, located at 9821 Colonnade Boulevard in San Antonio, Texas. In addition to this presentation, Powerhouse Therapeutics will also share updates during the symposium’s poster reception on Friday, October 10, 2025.
“We look forward to sharing our progress with PH102 at SALCS,” said Vincent T. Pham, Co-Founder and CEO of Powerhouse Therapeutics. “Liver cancer remains one of the most challenging oncology indications, and we believe PH102 has the potential to fundamentally shift how patients with hepatocellular carcinoma are treated.”
The San Antonio Liver Cancer Symposium is a premier international meeting that brings together leading researchers, clinicians, and industry experts to highlight the latest advances in liver cancer biology and therapy.
About Powerhouse therapeutics
Powerhouse Therapeutics Inc is a biotechnology company developing cell-based therapies that tackle treatment resistance in solid tumors and fibrotic diseases. Built on our proprietary Immune Triad Therapy with Armed CAR T-cell Supercharger (IT-ACTS) platform, we engineer multimodal living drugs that deliver targeted payloads, remodel the tumor microenvironment, and restore tissue homeostasis. Our lead candidate, PH102, is an autologous IT-ACTS therapy poised for clinical entry, with off-the-shelf and anti-fibrotic programs advancing in parallel. Founded by leading academic scientists, we combine academic rigor with translational speed to deliver paradigm-shifting therapies for all patients.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including those regarding our future results of operations and financial position, business strategy, product candidates, and planned clinical trials, are forward-looking statements. You can identify these statements by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “potential,” “continue,” or similar expressions, as well as discussions of future events or trends.
Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, delays or failures in product development, clinical-trial outcomes that differ from preclinical data, adverse decisions by regulatory authorities, challenges in manufacturing or supply chains, our ability to secure and protect intellectual-property rights, competition in the marketplace, changes in healthcare regulations, and our need for additional financing. More information about these and other risks is included in our filings with the U.S. Securities and Exchange Commission.
We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Powerhouse Therapeutics Inc undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or circumstances, except as required by law.
